Business
Press Release Mar 08 2023
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated March 08, 2023, titled "Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Thiamine Hydrochloride Injection USP".
About this update from Caplin Point Laboratories Limited
[{"type":"text","content":" Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated March 08, 2023, titled \"Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Thiamine Hydrochloride Injection USP\". View Attachment","length":604,"tagName":"div"}]